All News

T%20cell.jpg

Targeting PD-1 in Rheumatoid Arthritis

Jack Cush, MD

The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.

Read Article
cost.price_.drugs_.pills_.jpg

The Cartel is Coming for Rheumatology

Eric Dein, MD

"What Do Blockbuster Drugs & The Black Market All Have in Common?" asked Dr. Madelaine Feldman at RheumNow Live 2025. They thrive, she explained, on market exclusivity "... until they don't." At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.

Read Article
Kavanaugh RNL 25

Combination biologics in PsA: are we there yet?

Adela Castro, MD

Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.

Read Article
RheumNow Podcast square

Valentine RNL 2025 Review (2.14.2025)

Jack Cush, MD

Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.

Read Article
lupus SLE

Obinutuzumab Efficacy in Active Lupus Nephritis

Jack Cush, MD

A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.

Read Article
Combination biologics in PsA: are we there yet? Combination therapy is well-established in rheumatoid arthritis, but its efficacy in psoriatic arthritis (PsA) remains uncertain. Despite effective treatment options, there is a need for solutions for patients unresponsive to… https://t.co/uqLnxLIktM https://t.co/awwaVPOZTu
Dr. John Cush RheumNow ( View Tweet)
February 5, 2025, the FDA granted Fast Track designation to ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory class III or class IV lupus nephritis, & nd SLE with extrarenal Dz… https://t.co/ywXUTKSoB2 https://t.co/Es0F63MBrk
Dr. John Cush RheumNow ( View Tweet)
The POWER of #plaquenil #Hydroxychloroquine works in #rheumatic #diseases by Old answer 👇 Alters liposomal membranes 🤷‍♀️ NEW ANSWER Inhibits TLR signalling 🔥 ⁩ #RNL2025 Mary *Peggy Crow #SLE #systemic #lupus #erythematosus https://t.co/j2YQjVIpcy
Dr. John Cush RheumNow ( View Tweet)
#Benralizumab vs #Mepolizumab both work for #EGPA Which to use? 🤷‍♀️ perhaps some advantage of more steroid sparing w Benralizumab? ? JAKi ?long acting #IL5i #RNL2025 ⁦@RheumNow⁩ https://t.co/UkthHpNRIq

Links:

Janet Pope Janetbirdope ( View Tweet)
Obinutuzumab Efficacy in Active Lupus Nephritis A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis. https://t.co/e1cDvJcC9g https://t.co/HUDd1ocAvc

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Treatment of sclerosing skin disease: -Progression: inflammation➡️sclerosis➡️ atrophy -Existing therapies target inflammation not sclerosis-poorly developed ttx for sclerosis -First aspect is determining disease state, depth of involvement, extracutaneous manifestations… https://t.co/lYQRW2yDRG https://t.co/DQZjYKS2Ks

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o

Links:

Dr. John Cush RheumNow ( View Tweet)
-HS ttx👇 1. Lifestyle changes: smoking cessation, obesity. 2. Management of comorbidities. 3. 🔍HS- related autoimmune disorders. 4. FDA approved biologics: -Adalimumab (PIONEER 1&2) -Secukinumab (SUNRISE, SUNSHINE) -Bimekizumab (BE HEARD 1&2) "Theres no such… https://t.co/G5Voxrm3Kt https://t.co/dLGtoFZMd1

Links:

Adela Castro AdelaCastro222 ( View Tweet)
P2 Trial: DEU in PsA Encouraging results for DCV 6 and 12 mg qd. ACR20 63% for DCV 12 mg (p=0.0004) Not yet FDA approved for PsA, only PsO Pending P3 P2: DEU in SLE - PAISLEY Improved SRI(4), CLASI-50 at w32 Merola #RNL2025 @RheumNow https://t.co/RV7OPaZWjx

Links:

Eric Dein ericdeinmd ( View Tweet)
#RNL2025 @RheumNow JAKi in DM: @JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response 145 case reports for tofa, bari, ruxolitinib. Role in helping calcinosis? Pruritu? Brepocitinib (JAK1/TYK2i) study

Eric Dein ericdeinmd ( View Tweet)

Great graph from @AlexisOgdie on the effect of biologic treatment on PsA development in psoriasis. Obvious front-loading in those who need systemic therapy. But over time those who don't appear to develop more PsA @RheumNow @RNL2025 https://t.co/UxUZyKb0NA

Links:

Richard Conway RichardPAConway ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/qjtr4yz8Ot https://t.co/RUZmLgsmTv
Dr. John Cush RheumNow ( View Tweet)
🏈Kick-off of @RheumNow w Jeff Curtis #RNL2025 🏈 AI in RA? Can help with Rheum Boards Questions, though AI is not confident in answers May not be better than paper charts for triage Other roles: pt chatbot, AI scribe, research populations, generate DDx, consume guidelines https://t.co/X43DCmt0Ov

Links:

Eric Dein ericdeinmd ( View Tweet)
Can #AI help us determine the 👇 Right drug At Right time Pipe dream? Or to use #artificial #intelligence term ➡️ a #hallucination? garbage in ➡️➡️garbage out Most predictions of drug response are same: multimorbid multiRx failures Nonadherent poverty #RNL25 @RheumNow https://t.co/70SRp8BnCl

Links:

Janet Pope Janetbirdope ( View Tweet)
Rituximab is FDA approved for treatment of moderate to severe pemphigus, but 20% may relapse in 1st Yr. Study of 87 pts shows the efficacy of repeat 6 mos RTX in A) those with persistent Dz activity and B) anyone w/ predictors of relapse (PDAI score, DSG1 or DSG3 abs)… https://t.co/IhqdGWVcdp https://t.co/MKhDpa5zHv
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×